Introduces Full Year 2021 Premium Revenue Growth Expectation of 20 Percent
|
Three Months Ended |
|
Six Months Ended |
|||||||||
|
|
|
|
|||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||
|
(In millions, except per share results) |
|||||||||||
Premium Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Pre-Tax Income |
|
|
|
|
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
|
|
|
|
GAAP EPS – Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EPS – Diluted (1) |
|
|
|
|
|
|
|
|
|
|
|
|
MCR |
82.3 |
% |
|
85.6 |
% |
|
84.3 |
% |
|
85.5 |
% |
|
G&A Ratio |
7.5 |
% |
|
7.8 |
% |
|
7.2 |
% |
|
7.6 |
% |
|
Effective Tax Rate |
30.0 |
% |
|
24.0 |
% |
|
29.9 |
% |
|
23.9 |
% |
|
After-Tax Margin |
6.0 |
% |
|
4.7 |
% |
|
5.0 |
% |
|
4.7 |
% |
|
__________________ |
||||||||||||
(1) See reconciliation of GAAP EPS to Non-GAAP Adjusted EPS at the end of this release. |
Quarter Highlights:
-
Premium revenue was
$4.4 billion for the second quarter of 2020, an 8.0% increase compared to the second quarter of 2019. - Medical care ratio (MCR) was 82.3% for the second quarter of 2020, compared to 85.6% for the second quarter of 2019.
- General and administrative (G&A) expense ratio decreased to 7.5% for the second quarter of 2020, compared to 7.8% for the second quarter of 2019.
- After-tax margin was 6.0% for the second quarter of 2020, compared to 4.7% for the second quarter of 2019.
-
Net income was
$276 million for the second quarter of 2020, compared to$196 million for second quarter of 2019. -
The Company estimates that the impacts of COVID-19 increased second quarter after-tax income by approximately
$65 million to$100 million , or$1.10 to$1.65 per diluted share. -
The Company’s full year earnings guidance range remains at
$11.20 to$11.70 per diluted share. -
The Company introduced full year 2021 premium revenue guidance of approximately
$21.5 billion , or 20% growth over 2020.
“Despite the unprecedented environment of the ongoing COVID-19 pandemic, our company performed well in the second quarter,” said
Kentucky RFP Win and Passport Acquisition
In
In
Acquisition of YourCare Assets Completed
On
Quarterly Performance Review
Premium Revenue
Premium revenue for the second quarter of 2020 increased 8.0% to
For the six months ended
Medical Care Ratio
The consolidated MCR for the second quarter of 2020 improved to 82.3%, compared to 85.6% for the second quarter of 2019, reflecting the impact of reduced demand for medical services across all programs due to the COVID-19 pandemic, partially offset by COVID-related premium rate refunds, the impact of lower pricing in the Marketplace program, and direct COVID-19 medical costs.
MCR by line of business:
- Medicaid MCR: decreased to 83.6%, compared to 88.1% for the second quarter of 2019, reflecting the impact of reduced demand for medical services due to the COVID-19 pandemic, partially offset by COVID-related premium reductions and direct COVID-19 medical costs.
- Medicare MCR: decreased to 80.0%, compared to 85.2% for the second quarter of 2019, due to rate increases and the aforementioned reduced demand for medical services.
- Marketplace MCR: increased to 74.0%, compared to 67.2% for the second quarter of 2019, which is in line with expectations and reflects the lower pricing the Company enacted in 2020.
The MCR for the six months ended
General and Administrative Expense Ratio
General and administrative expenses decreased to 7.5% of total revenues for the second quarter of 2020, compared to 7.8% for the second quarter of 2019.
For the six months ended
Balance Sheet
Cash and investments at the parent company amounted to
On
Cash Flow
Operating cash flows for the six months ended
Guidance
Given the environmental uncertainty that is expected to exist through the end of the year, the Company has not adjusted its full year earnings guidance of
The Company has increased its full year 2020 total revenue outlook to approximately
The Company introduced full year 2021 premium revenue guidance of approximately
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s second quarter 2020 results at
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and our accompanying oral remarks contain forward-looking statements regarding our 2020 guidance, as well as our plans, expectations, and our anticipation regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements” and “Risk Factors” in our Annual Report on Form 10-K for the year ended
These reports can be accessed under the investor relations tab of our website or on the SEC’s website at sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this release represent our judgment as of
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME |
|||||||||||||||
|
|
|
|
||||||||||||
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
|
(In millions, except per-share amounts) |
||||||||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
4,372 |
|
|
$ |
4,049 |
|
|
$ |
8,676 |
|
|
$ |
8,001 |
|
Premium tax revenue |
157 |
|
|
110 |
|
|
307 |
|
|
248 |
|
||||
Health insurer fees reimbursed |
71 |
|
|
— |
|
|
137 |
|
|
— |
|
||||
Investment income and other revenue |
18 |
|
|
34 |
|
|
47 |
|
|
63 |
|
||||
Total revenue |
4,618 |
|
|
4,193 |
|
|
9,167 |
|
|
8,312 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Medical care costs |
3,598 |
|
|
3,466 |
|
|
7,314 |
|
|
6,837 |
|
||||
General and administrative expenses |
345 |
|
|
328 |
|
|
662 |
|
|
630 |
|
||||
Premium tax expenses |
157 |
|
|
110 |
|
|
307 |
|
|
248 |
|
||||
Health insurer fees |
71 |
|
|
— |
|
|
139 |
|
|
— |
|
||||
Depreciation and amortization |
21 |
|
|
22 |
|
|
41 |
|
|
47 |
|
||||
Other |
2 |
|
|
2 |
|
|
6 |
|
|
5 |
|
||||
Total operating expenses |
4,194 |
|
|
3,928 |
|
|
8,469 |
|
|
7,767 |
|
||||
Operating income |
424 |
|
|
265 |
|
|
698 |
|
|
545 |
|
||||
Other expenses, net: |
|
|
|
|
|
|
|
||||||||
Interest expense |
24 |
|
|
22 |
|
|
45 |
|
|
45 |
|
||||
Other expense (income), net |
5 |
|
|
(14) |
|
|
5 |
|
|
(17) |
|
||||
Total other expenses, net |
29 |
|
|
8 |
|
|
50 |
|
|
28 |
|
||||
Income before income tax expense |
395 |
|
|
257 |
|
|
648 |
|
|
517 |
|
||||
Income tax expense |
119 |
|
|
61 |
|
|
194 |
|
|
123 |
|
||||
Net income |
$ |
276 |
|
|
$ |
196 |
|
|
$ |
454 |
|
|
$ |
394 |
|
|
|
|
|
|
|
|
|
||||||||
Net income per share - Diluted |
$ |
4.65 |
|
|
$ |
3.06 |
|
|
$ |
7.54 |
|
|
$ |
6.04 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted average shares outstanding |
59.4 |
|
|
64.0 |
|
|
60.2 |
|
|
65.1 |
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating Statistics: |
|
|
|
|
|
|
|
||||||||
Medical care ratio |
82.3 |
% |
|
85.6 |
% |
|
84.3 |
% |
|
85.5 |
% |
||||
G&A ratio |
7.5 |
% |
|
7.8 |
% |
|
7.2 |
% |
|
7.6 |
% |
||||
Premium tax ratio |
3.5 |
% |
|
2.6 |
% |
|
3.4 |
% |
|
3.0 |
% |
||||
Effective income tax rate |
30.0 |
% |
|
24.0 |
% |
|
29.9 |
% |
|
23.9 |
% |
||||
After-tax margin |
6.0 |
% |
|
4.7 |
% |
|
5.0 |
% |
|
4.7 |
% |
CONSOLIDATED BALANCE SHEETS |
|||||||
|
|
|
|
||||
|
|
|
|
||||
|
2020 |
|
2019 |
||||
|
Unaudited |
|
|
||||
|
(Dollars in millions,
|
||||||
ASSETS |
|||||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
3,303 |
|
|
$ |
2,452 |
|
Investments |
1,906 |
|
|
1,946 |
|
||
Receivables |
1,580 |
|
|
1,406 |
|
||
Prepaid expenses and other current assets |
273 |
|
|
163 |
|
||
Total current assets |
7,062 |
|
|
5,967 |
|
||
Property, equipment, and capitalized software, net |
399 |
|
|
385 |
|
||
|
164 |
|
|
172 |
|
||
Restricted investments |
87 |
|
|
79 |
|
||
Deferred income taxes |
65 |
|
|
79 |
|
||
Other assets |
99 |
|
|
105 |
|
||
Total assets |
$ |
7,876 |
|
|
$ |
6,787 |
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
Current liabilities: |
|
|
|
||||
Medical claims and benefits payable |
$ |
1,960 |
|
|
$ |
1,854 |
|
Amounts due government agencies |
865 |
|
|
664 |
|
||
Accounts payable, accrued liabilities and other |
876 |
|
|
502 |
|
||
Deferred revenue |
54 |
|
|
249 |
|
||
Total current liabilities |
3,755 |
|
|
3,269 |
|
||
Long-term debt |
1,812 |
|
|
1,237 |
|
||
Finance lease liabilities |
229 |
|
|
231 |
|
||
Other long-term liabilities |
84 |
|
|
90 |
|
||
Total liabilities |
5,880 |
|
|
4,827 |
|
||
Stockholders’ equity: |
|
|
|
||||
Common stock, |
— |
|
|
— |
|
||
Preferred stock, |
— |
|
|
— |
|
||
Additional paid-in capital |
166 |
|
|
175 |
|
||
Accumulated other comprehensive income |
32 |
|
|
4 |
|
||
Retained earnings |
1,798 |
|
|
1,781 |
|
||
Total stockholders’ equity |
1,996 |
|
|
1,960 |
|
||
Total liabilities and stockholders’ equity |
$ |
7,876 |
|
|
$ |
6,787 |
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
|
|
||||||
|
Six Months Ended |
||||||
|
|
||||||
|
2020 |
|
2019 |
||||
|
(In millions) |
||||||
Operating activities: |
|
|
|
||||
Net income |
$ |
454 |
|
|
$ |
394 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
41 |
|
|
47 |
|
||
Deferred income taxes |
6 |
|
|
19 |
|
||
Share-based compensation |
28 |
|
|
19 |
|
||
Loss (gain) on debt repayment |
5 |
|
|
(17) |
|
||
Other, net |
(1) |
|
|
7 |
|
||
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables |
(174) |
|
|
91 |
|
||
Prepaid expenses and other current assets |
(157) |
|
|
18 |
|
||
Medical claims and benefits payable |
106 |
|
|
(194) |
|
||
Amounts due government agencies |
201 |
|
|
17 |
|
||
Accounts payable, accrued liabilities and other |
251 |
|
|
(61) |
|
||
Deferred revenue |
(195) |
|
|
(181) |
|
||
Income taxes |
184 |
|
|
(3) |
|
||
Net cash provided by operating activities |
749 |
|
|
156 |
|
||
Investing activities: |
|
|
|
||||
Purchases of investments |
(670) |
|
|
(1,162) |
|
||
Proceeds from sales and maturities of investments |
750 |
|
|
791 |
|
||
Purchases of property, equipment, and capitalized software |
(45) |
|
|
(20) |
|
||
Other, net |
3 |
|
|
(2) |
|
||
Net cash provided by (used in) investing activities |
38 |
|
|
(393) |
|
||
Financing activities: |
|
|
|
||||
Proceeds from senior notes offering, net of issuance costs |
789 |
|
|
— |
|
||
Repayment of term loan facility |
(600) |
|
|
— |
|
||
Common stock purchases |
(453) |
|
|
— |
|
||
Proceeds from borrowings under term loan facility |
380 |
|
|
220 |
|
||
Cash paid for partial termination of warrants |
(30) |
|
|
(424) |
|
||
Cash paid for partial settlement of conversion option |
(27) |
|
|
(473) |
|
||
Cash received for partial settlement of call option |
27 |
|
|
473 |
|
||
Repayment of principal amount of convertible senior notes |
(12) |
|
|
(185) |
|
||
Other, net |
(3) |
|
|
27 |
|
||
Net cash provided by (used in) financing activities |
71 |
|
|
(362) |
|
||
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents |
858 |
|
|
(599) |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period |
2,508 |
|
|
2,926 |
|
||
Cash, cash equivalents, and restricted cash and cash equivalents at end of period |
$ |
3,366 |
|
|
$ |
2,327 |
|
UNAUDITED HEALTH PLANS SEGMENT DATA (Dollars in millions) |
||||||||
|
|
|
|
|
|
|||
|
|
|
|
|
|
|||
|
2020 |
|
2019 |
|
2019 |
|||
Ending Membership by Government Program: |
|
|
|
|
|
|||
Medicaid |
3,122,000 |
|
|
2,956,000 |
|
|
2,962,000 |
|
Medicare |
108,000 |
|
|
101,000 |
|
|
100,000 |
|
Marketplace |
325,000 |
|
|
274,000 |
|
|
308,000 |
|
Total |
3,555,000 |
|
|
3,331,000 |
|
|
3,370,000 |
|
|
|
|
|
|
|
|||
Ending Membership by Health Plan: |
|
|
|
|
|
|||
|
572,000 |
|
|
565,000 |
|
|
590,000 |
|
|
131,000 |
|
|
132,000 |
|
|
142,000 |
|
|
242,000 |
|
|
224,000 |
|
|
221,000 |
|
|
377,000 |
|
|
362,000 |
|
|
360,000 |
|
|
329,000 |
|
|
288,000 |
|
|
297,000 |
|
|
167,000 |
|
|
176,000 |
|
|
200,000 |
|
|
145,000 |
|
|
131,000 |
|
|
130,000 |
|
|
352,000 |
|
|
341,000 |
|
|
360,000 |
|
|
913,000 |
|
|
832,000 |
|
|
811,000 |
|
Other (1) |
327,000 |
|
|
280,000 |
|
|
259,000 |
|
Total |
3,555,000 |
|
|
3,331,000 |
|
|
3,370,000 |
|
__________________ | ||
(1) |
“Other” includes the |
|
Three Months Ended |
||||||||||||||||||||
|
2020 |
|
2019 |
||||||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
3,375 |
|
|
$ |
2,822 |
|
|
83.6 |
% |
|
$ |
3,067 |
|
|
$ |
2,703 |
|
|
88.1 |
% |
Medicare |
630 |
|
|
505 |
|
|
80.0 |
|
|
572 |
|
|
488 |
|
|
85.2 |
|
||||
Marketplace |
367 |
|
|
271 |
|
|
74.0 |
|
|
410 |
|
|
275 |
|
|
67.2 |
|
||||
Consolidated |
$ |
4,372 |
|
|
$ |
3,598 |
|
|
82.3 |
% |
|
$ |
4,049 |
|
|
$ |
3,466 |
|
|
85.6 |
% |
|
Six Months Ended |
||||||||||||||||||||
|
2020 |
|
2019 |
||||||||||||||||||
|
Premium
|
|
Medical
|
|
MCR (1) |
|
Premium
|
|
Medical
|
|
MCR (1) |
||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicaid |
$ |
6,661 |
|
|
$ |
5,743 |
|
|
86.2 |
% |
|
$ |
6,071 |
|
|
$ |
5,361 |
|
|
88.3 |
% |
Medicare |
1,264 |
|
|
1,022 |
|
|
80.8 |
|
|
1,123 |
|
|
954 |
|
|
85.0 |
|
||||
Marketplace |
751 |
|
|
549 |
|
|
73.1 |
|
|
807 |
|
|
522 |
|
|
64.7 |
|
||||
Consolidated |
$ |
8,676 |
|
|
$ |
7,314 |
|
|
84.3 |
% |
|
$ |
8,001 |
|
|
$ |
6,837 |
|
|
85.5 |
% |
__________________ |
||
(1) |
The MCR represents medical costs as a percentage of premium revenue. |
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liability includes an additional reserve to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amount by which the original estimate of claims and benefits payable at the beginning of the year was more than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Six Months Ended |
|
Year Ended
|
||||||||
|
|
|
|||||||||
|
2020 |
|
2019 |
|
|||||||
|
Unaudited |
|
|
||||||||
Medical claims and benefits payable, beginning balance |
$ |
1,854 |
|
|
$ |
1,961 |
|
|
$ |
1,961 |
|
Components of medical care costs related to: |
|
|
|
|
|
||||||
Current year |
7,372 |
|
|
7,069 |
|
|
14,176 |
|
|||
Prior year |
(58) |
|
|
(232) |
|
|
(271) |
|
|||
Total medical care costs |
7,314 |
|
|
6,837 |
|
|
13,905 |
|
|||
Change in non-risk and other provider payables |
(34) |
|
|
4 |
|
|
24 |
|
|||
Payments for medical care costs related to: |
|
|
|
|
|
||||||
Current year |
5,688 |
|
|
5,585 |
|
|
12,554 |
|
|||
Prior year |
1,486 |
|
|
1,450 |
|
|
1,482 |
|
|||
Total paid |
7,174 |
|
|
7,035 |
|
|
14,036 |
|
|||
Medical claims and benefits payable, ending balance |
$ |
1,960 |
|
|
$ |
1,767 |
|
|
$ |
1,854 |
|
|
|
|
|
|
|
||||||
Days in claims payable, fee for service (1) |
52 |
|
|
48 |
|
|
50 |
|
______________________ |
||
(1) |
Claims payable includes primarily claims incurred but not paid, or IBNP. It also includes certain fee-for-service payables reported in medical claims and benefits payable amounting to |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-generally accepted accounting principles, or non-GAAP, financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Earnings before interest, taxes, depreciation and amortization (“EBITDA”): GAAP net income less depreciation and amortization, interest expense and income tax expense. The Company believes that EBITDA is helpful to investors in assessing the Company’s ability to meet the cash demands of its operating units.
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
|
|
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
Net income |
$ |
276 |
|
|
$ |
196 |
|
|
$ |
454 |
|
|
$ |
394 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
21 |
|
|
22 |
|
|
41 |
|
|
47 |
|
||||
Interest expense |
24 |
|
|
22 |
|
|
45 |
|
|
45 |
|
||||
Income tax expense |
119 |
|
|
61 |
|
|
194 |
|
|
123 |
|
||||
EBITDA |
$ |
440 |
|
|
$ |
301 |
|
|
$ |
734 |
|
|
$ |
609 |
|
Adjusted net income: GAAP net income less amortization of intangible assets, restructuring costs, loss (gain) on debt repayment, and the aggregate income tax effect calculated at the blended federal and state statutory tax rate. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance exclusive of the non-cash impact of the amortization of purchased intangibles and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted net income per diluted share: Adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||||||||||||||
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||||||||||||||||||
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
|
Amount |
|
Per
|
||||||||||||||||
Net income |
$ |
276 |
|
|
$ |
4.65 |
|
|
$ |
196 |
|
|
$ |
3.06 |
|
|
$ |
454 |
|
|
$ |
7.54 |
|
|
$ |
394 |
|
|
$ |
6.04 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Amortization of intangible assets |
4 |
|
|
0.06 |
|
|
4 |
|
|
0.07 |
|
|
8 |
|
|
0.13 |
|
|
9 |
|
|
0.14 |
|
||||||||
Restructuring costs |
2 |
|
|
0.04 |
|
|
2 |
|
|
0.03 |
|
|
6 |
|
|
0.11 |
|
|
5 |
|
|
0.07 |
|
||||||||
Loss (gain) on debt repayment |
5 |
|
|
0.08 |
|
|
(14) |
|
|
(0.23) |
|
|
5 |
|
|
0.08 |
|
|
(17) |
|
|
(0.27) |
|
||||||||
Subtotal, adjustments |
11 |
|
|
0.18 |
|
|
(8) |
|
|
(0.13) |
|
|
19 |
|
|
0.32 |
|
|
(3) |
|
|
(0.06) |
|
||||||||
Income tax effect |
(2) |
|
|
(0.04) |
|
|
1 |
|
|
0.03 |
|
|
(4) |
|
|
(0.07) |
|
|
— |
|
|
0.01 |
|
||||||||
Adjustments, net of tax |
9 |
|
|
0.14 |
|
|
(7) |
|
|
(0.10) |
|
|
15 |
|
|
0.25 |
|
|
(3) |
|
|
(0.05) |
|
||||||||
Adjusted net income |
$ |
285 |
|
|
$ |
4.79 |
|
|
$ |
189 |
|
|
$ |
2.96 |
|
|
$ |
469 |
|
|
$ |
7.79 |
|
|
$ |
391 |
|
|
$ |
5.99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005809/en/
Investor Contact:
Media Contact:
Source: